Solentim is ‘attending’ BioProcess International Europe Virtual
We are happy to announce that Solentim will be taking part in BPI Europe’s 100% virtual conference, taking place 13-17 July.
Mark Stockdale, Amalgamator of Business and Biology at Solentim, will be presenting on July 14th, 13:50. His talk, entitled “Total Cell Line Development – A Holistic A-Z Approach for Scientists Planning A Cell Line Development Lab” will be streamed online for all attendees.
This is Europe’s leading bioprocessing event for accelerating biologics, MABs, vaccines and novel products to commercial success.
Mark Truesdale, CEO at Solentim, commented: “This is a key event in Europe’s bioprocessing calendar and we are delighted to be able to take part despite the global pandemic. Continuing to progress research, collaboration and discussion is more important than ever at the moment, and we are excited to get stuck in.”
Mark Stockdale is a keen technology pathfinder and works within Solentim to amalgamate the technical and business functions of the company. Prior to joining Solentim, he worked as a Group Leader at Horizon Discovery Ltd, a scientist for Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs, he provides great insight into the future technology requirements in stable cell line development.
The event enables the bioprocessing community to stay connected, strategize and share ideas in a safe, responsible way. The program features sessions on cell line development & engineering, cell culture & upstream process development, downstream processing, analytics & control strategies, vaccines manufacture and viral safety.
Please get in touch to find out how Solentim can help you accelerate the development of your Master Cell Banks and ensure you are confidently prepared for regulatory review